Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, No. 27 (Jul. 6, 2004), pp. 10127-10131 (5 pages) The lectin complement pathway in innate immunity is closely ...
The classical complement pathway typically requires antigen—antibody complexes (immune complexes) for activation (specific immune response), whereas the alternative pathway can be activated by C3 ...
– First patient dosed in Phase 2 study of ANX005 C1q targeted mAb – SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage ...
SOUTH SAN FRANCISCO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing novel therapies for patients with ...
The classical complement pathway typically requires antigen—antibody complexes (immune complexes) for activation (specific immune response), whereas the alternative pathway can be activated by C3 ...
“After more than a decade of groundbreaking research targeting the early classical complement pathway, we are excited to have reached an important step in the clinical development of ANX1502, our ...
A new study uncovers a surprising mechanism by which the SARS-CoV-2 virus, responsible for COVID-19, might cause immune-mediated tissue damage by targeting cells it has never infected. Science X Daily ...
Dianthus Therapeutics, Inc.'s DNTH103 is being evaluated in the phase 2 MaGic trial, which is targeting patients with generalized myasthenia gravis. The global myasthenia gravis treatment market size ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback